Exome Asset Management LLC Purchases 25,600 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Exome Asset Management LLC grew its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) by 20.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 149,600 shares of the company’s stock after purchasing an additional 25,600 shares during the quarter. Exome Asset Management LLC owned approximately 0.25% of Pliant Therapeutics worth $1,677,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of PLRX. The Manufacturers Life Insurance Company boosted its position in Pliant Therapeutics by 1.4% during the second quarter. The Manufacturers Life Insurance Company now owns 83,483 shares of the company’s stock valued at $897,000 after acquiring an additional 1,191 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Pliant Therapeutics by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock valued at $131,000 after purchasing an additional 4,607 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Pliant Therapeutics by 1.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 305,322 shares of the company’s stock valued at $3,282,000 after purchasing an additional 5,152 shares in the last quarter. Summit Securities Group LLC acquired a new stake in Pliant Therapeutics during the second quarter worth approximately $59,000. Finally, Ensign Peak Advisors Inc increased its holdings in Pliant Therapeutics by 39.1% in the second quarter. Ensign Peak Advisors Inc now owns 35,368 shares of the company’s stock worth $380,000 after purchasing an additional 9,950 shares in the last quarter. 97.30% of the stock is currently owned by institutional investors and hedge funds.

Pliant Therapeutics Stock Performance

Shares of PLRX stock opened at $13.30 on Friday. Pliant Therapeutics, Inc. has a 12 month low of $10.22 and a 12 month high of $19.62. The firm has a market capitalization of $809.36 million, a PE ratio of -3.98 and a beta of 1.05. The firm has a fifty day simple moving average of $13.88 and a two-hundred day simple moving average of $12.77. The company has a current ratio of 10.26, a quick ratio of 10.26 and a debt-to-equity ratio of 0.09.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PLRX. Leerink Partnrs raised shares of Pliant Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Leerink Partners assumed coverage on shares of Pliant Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $33.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $40.50.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.